- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04814004
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
March 24, 2021 updated by: Kai Lin Xu; Jun Nian Zheng
This study aims to evaluate the safety and feasibility of hCD19.IL15.CAR-iNKT cells in treating patients with relapsed/refractory/high-risk B-cell tumors.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
CD19 CAR-T has been shown to treat a variety of refractory or recurrent B-cell tumors.
Because most CAR-T cells are generated from the patient's own T cells and are individualized products, and there are individual differences between patients, the generation of customized CAR-T cells is an expensive and time-consuming process.
Universal CAR- iNKT cells are an ideal product for cell therapy.
In this study, we prepared universal iNKT cells expressing hCD19 CAR and IL-15 to treat refractory, relapsed, or high-risk B-cell tumors.
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jiang Cao, Ph.D
- Phone Number: 86-516-85802007
- Email: zimu05067@163.com
Study Contact Backup
- Name: Ming Shi, Ph.D
- Phone Number: 86-516-85802635
- Email: sm200@sohu.com
Study Locations
-
-
Jiangsu
-
Xuzhou, Jiangsu, China, 221000
- Recruiting
- The Affiliated Hospital Of Xuzhou Medical University
-
Contact:
- Jiang Cao, M.D., Ph.D.
- Phone Number: 86-516-85802007
- Email: zimu05067@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 70 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients aged 5-70 years;
- The patient's ECOG score was ≤2, and the expected survival time of > was 12 weeks.
- The patient was diagnosed with B-cell tumor by pathological and histological examination and had no effective treatment options, such as recurrence after chemotherapy or hematopoietic stem cell transplantation. Or the patient voluntarily chooses the infusion of CAR-INKT cells as the first treatment.
B cell tumors include the following three types:
- B-cell acute lymphocytic leukemia (B-ALL);
- Inert B-cell lymphoma (CLL, FL, MZL, LPL, HCL);
- Aggressive B-cell lymphoma (DLBCL, BL, MCL);
Subject:
- Residual lesions remain after primary treatment and are not suitable for HSCT (Auto/Allo-HSCT);
- relapse after complete response (CR1) and unsuitable for allogeneic/autologous HSCT;
- Patients with high risk factors;
- relapse or no remission after hematopoietic stem cell transplantation or cellular immunotherapy.
- having measurable or evaluable lesions;
The main tissues and organs of the patient function well:
- Liver function: ALT/AST < 3 times the upper limit of normal (ULN);
- Renal function: creatinine < 220μmol/L;
- Lung function: indoor oxygen saturation ≥95%;
- Heart function: left ventricular ejection fraction (LVEF) ≥40%.
- Patients or their legal guardians voluntarily participate and sign the informed consent.
Exclusion Criteria:
- Pregnant or lactating women, or women who plan to become pregnant within six months;
- Infectious diseases (e.g. HIV, active hepatitis B or C infection, active tuberculosis, etc.);
- GVHD;
- Abnormal vital signs and failure to cooperate with the examination;
- People with mental or mental illness who are unable to cooperate with treatment and efficacy evaluation;
- People with high allergic constitution or severe allergic history, especially those allergic to IL-2;
- Subjects with systemic infection or severe local infection need anti-infection therapy;
- Complicated with dysfunction of heart, lung, brain, liver, kidney and other important organs;
- Any unstable systemic disease: including but not limited to unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia (within 6 months before screening), myocardial infarction (within 6 months before screening), congestive heart failure (NYHA classification ≥III);
- Doctors believe that there are other reasons for not being included in treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: hCD19.IL15.CAR-iNKT cells
Dose escalation follows the accelerated titration and the standard 3+3 dose escalation design.
A total of 3 dose levels are set for subjects.
|
Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity
Time Frame: Baseline up to 28 days after T cell infusion
|
Adverse events assessed according to NCI-CTCAE v5.0 criteria
|
Baseline up to 28 days after T cell infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRD negative overall response rate (MRD- ORR)
Time Frame: 3 months
|
Assessment of MRD negative overall response rate (MRD- ORR) at 3 months of treatment
|
3 months
|
Overall response rate (ORR)
Time Frame: Month 6, 12, 18 and 24
|
Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24
|
Month 6, 12, 18 and 24
|
Event-free survival (EFS)
Time Frame: Month 6, 12, 18 and 24
|
Assessment of EFS at Month 6, 12, 18 and 24
|
Month 6, 12, 18 and 24
|
Overall survival (OS)
Time Frame: Month 6, 12, 18 and 24
|
Assessment of OS at Month 6, 12, 18 and 24
|
Month 6, 12, 18 and 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Kailin Xu, Ph.d, The Affiliated Hospital Of Xuzhou Medical University
- Study Director: Junnian Zheng, Ph.D, Xuzhou Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 19, 2021
Primary Completion (Anticipated)
April 1, 2023
Study Completion (Anticipated)
April 1, 2024
Study Registration Dates
First Submitted
March 22, 2021
First Submitted That Met QC Criteria
March 22, 2021
First Posted (Actual)
March 24, 2021
Study Record Updates
Last Update Posted (Actual)
March 29, 2021
Last Update Submitted That Met QC Criteria
March 24, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XYFY2021-KL062
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on B-cell Lymphoma
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
Nathan DenlingerBristol-Myers SquibbRecruitingB-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditionsUnited States
-
AstraZenecaRecruitingFollicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin LymphomaKorea, Republic of, United States, Japan, Australia, Taiwan
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Massachusetts General HospitalVarian Medical SystemsRecruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
-
University of ChicagoMerck Sharp & Dohme LLCRecruitingLymphoma | Lymphoma, B-Cell | B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell LymphomaUnited States
-
Curocell Inc.RecruitingHigh-grade B-cell Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Transformed Follicular Lymphoma (TFL) | Refractory Large B-cell Lymphoma | Relapsed Large B-cell LymphomaKorea, Republic of
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University of NebraskaBristol-Myers SquibbRecruitingFollicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Active, not recruitingDiffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma... and other conditionsUnited States
Clinical Trials on hCD19.IL15.CAR-iNKT
-
Chongqing Public Health Medical CenterZhejiang Qixin Biotech; Chongqing Sidemu BiotechUnknown
-
M.D. Anderson Cancer CenterRecruitingAdvanced Renal Cell Carcinoma | Advanced Mesothelioma | Advanced OsteosarcomaUnited States
-
M.D. Anderson Cancer CenterRecruitingB-Cell Lymphoma | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)United States
-
M.D. Anderson Cancer CenterRecruiting
-
M.D. Anderson Cancer CenterCompletedChronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | B-Lymphoid Malignancies | Non-hodgkin LymphomaUnited States